id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dti-2593	Inno, Alessandro; Fabiana Marchetti; Matteo Valerio; Niccolò Giaj Levra; Filippo Alongi; Giovanni Foti; Stefania Gori	Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report	2023	2	.pdf	application/pdf	1492	70	47	The patient was started on sotorasib, and the brain magnetic resonance imaging (MRI) after 2 months of treatment showed stability of the cerebellar metastasis, reduction in size of the previ- ously treated parietal right metastasis with improvement of the surrounding edema, reduction in size of the previously untreated right frontal lobe metastasis, and no appearance of new brain metastases (Fig. 1). Full information is available at www.aboutscience.eu Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report Alessandro Inno1, Fabiana Marchetti1, Matteo Valerio1, Niccolò Giaj Levra2, Filippo Alongi2, Giovanni Foti3, Stefania Gori1 1Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy 2Advanced Radiation Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy 3Radiology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) - Italy ABSTRACT In the CodeBreaK 100 phase 2 study, sotorasib was active for patients with metastatic non-small cell lung cancer (NSCLC) harboring Kirsten rat sarcoma viral oncogene homologue (KRAS)	cache/dti-2593.pdf	txt/dti-2593.txt